Core Viewpoint - WuXi AppTec (药明康德) reported strong financial performance for the first three quarters of 2025, with significant growth in revenue and net profit, indicating a positive outlook for the company's core CRDMO business [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of RMB 32.86 billion, representing a year-on-year increase of 18.6% [1] - The revenue from continuing operations grew by 22.5% year-on-year [1] - The net profit attributable to shareholders reached RMB 12.076 billion, marking an impressive year-on-year growth of 84.84% [1] Future Projections - The company expects the revenue from continuing operations to return to double-digit growth, with the growth rate revised from 13-17% to 17-18% [1] - Overall annual revenue forecast has been adjusted from RMB 42.5-43.5 billion to RMB 43.5-44 billion [1] Business Focus - WuXi AppTec will concentrate on its core CRDMO business and aims to continuously improve operational efficiency [1] Order Backlog - As of September 30, 2025, the company had a backlog of orders for continuing operations amounting to RMB 59.88 billion, reflecting a year-on-year increase of 41.2% [1] Revenue Breakdown by Region - Revenue from U.S. clients was RMB 22.15 billion, up 31.9% year-on-year [1] - Revenue from European clients reached RMB 3.84 billion, growing by 13.5% year-on-year [1] - Revenue from Chinese clients was RMB 5.04 billion, with a modest increase of 0.5% year-on-year [1] - Revenue from other regions amounted to RMB 1.42 billion, showing a year-on-year growth of 9.2% [1]

Core Insights - The company reported strong financial performance for Q1-Q3 2025, with revenue of 32.86 billion yuan, a year-on-year increase of 18.6%, and a net profit of 12.08 billion yuan, reflecting a significant year-on-year growth of 84.8% [1] - The company has raised its revenue growth guidance for 2025 from 13-17% to 17-18%, driven by robust demand in core business areas and improved operational efficiency [2] - The company plans to divest its clinical research services business for 2.8 billion yuan, which is expected to help focus on core operations and accelerate global capacity expansion [2] Financial Performance - Revenue for Q1-Q3 2025 reached 32.86 billion yuan, with a 22.5% year-on-year increase in continuing operations revenue [1] - Adjusted non-IFRS net profit was 10.54 billion yuan, up 43.4% year-on-year, with a net profit margin of 32.1%, an increase of 5.6 percentage points year-on-year [1] - The company’s continuing operations backlog reached 59.88 billion yuan, a year-on-year increase of 41.2% [2] Business Segments - The small molecule CDMO and TIDES segments showed strong growth, with WuXi Chemistry generating 25.98 billion yuan in revenue, a year-on-year increase of 29.3% [2] - TIDES revenue surged by 121.1% year-on-year to 7.84 billion yuan, while D&M revenue increased by 14.1% year-on-year to 14.24 billion yuan [2] - The drug safety evaluation segment maintained industry leadership, with laboratory analysis and testing revenue of 1.08 billion yuan, reflecting a year-on-year increase of 2.7% [2] Profit Forecast and Valuation - The company has revised its earnings forecasts for 2025 and 2026 upwards by 6.0% and 2.8%, respectively, to 15.63 billion yuan and 14.82 billion yuan [3] - Current A-shares are valued at 19.8x and 20.9x PE for 2025 and 2026, while H-shares are valued at 19.3x and 20.1x PE for the same periods [3] - Target prices for A-shares and H-shares have been raised by 7.4% to 123.5 yuan and 7.1% to 135.0 yuan, respectively, indicating an upside potential of 19.0% and 22.2% [3]

Core Viewpoint - WuXi AppTec (02359) reported strong financial performance for the first three quarters of 2025, with significant revenue and profit growth, indicating a positive outlook for the company's core CRDMO business [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of RMB 32.86 billion, representing a year-on-year increase of 18.6% [1] - The revenue from continuing operations grew by 22.5% year-on-year [1] - The net profit attributable to shareholders reached RMB 12.076 billion, marking an impressive year-on-year growth of 84.84% [1] Future Outlook - The company expects revenue from continuing operations to return to double-digit growth, with the growth rate revised from 13-17% to 17-18% [1] - Overall annual revenue guidance has been raised from RMB 42.5-43.5 billion to RMB 43.5-44 billion [1] Business Focus - The company will concentrate on its core CRDMO business and aims to continuously improve operational efficiency [1] Order Backlog - As of September 30, 2025, the order backlog for continuing operations stood at RMB 59.88 billion, reflecting a year-on-year increase of 41.2% [1] Revenue Breakdown - For the first three quarters of 2025, revenue from continuing operations was RMB 32.45 billion, with contributions from various regions: - Revenue from U.S. clients was RMB 22.15 billion, up 31.9% year-on-year [1] - Revenue from European clients was RMB 3.84 billion, increasing by 13.5% [1] - Revenue from Chinese clients was RMB 5.04 billion, showing a slight growth of 0.5% [1] - Revenue from other regions was RMB 1.42 billion, up 9.2% [1]

Core Insights - WuXi AppTec (603259.SH/2359.HK) reported its Q3 financial results on October 26, 2025, highlighting significant growth in its TIDES business and advancements in production capacity [1] Financial Performance - The company achieved TIDES business revenue of 7.84 billion yuan in the first three quarters, representing a year-on-year increase of 121.1% [1] Production Capacity - WuXi AppTec has completed the construction of its Taiqing peptide production capacity ahead of schedule, with over 10 WL of solid-phase synthesis reaction vessels operational in Q3, one quarter earlier than previously anticipated [1]

Core Viewpoint - WuXi AppTec (603259) reported a significant increase in revenue and net profit for the first three quarters of 2025, driven by a focus on the CRDMO business model and operational efficiencies [1] Financial Performance - The company achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached 12.076 billion yuan, marking an impressive year-on-year increase of 84.84% [1] Business Strategy - The growth in performance is attributed to the company's ongoing focus and enhancement of its CRDMO business model, leading to sustained revenue growth [1] - Continuous optimization of production processes and operational efficiency contributed to improved capacity utilization and overall profitability [1] Additional Income Sources - The company also benefited from the sale of part of its stake in the joint venture WuXi XDC Cayman Inc., which further boosted its profits [1]

Group 1 - The core point of the article is that WuXi AppTec (603259.SH/02359) reported a record high revenue for the third quarter of 2025, with a total revenue of 32.86 billion yuan for the first three quarters, representing a year-on-year growth of 18.6% [1] - The company has raised its full-year revenue target to 43.5-44 billion yuan, indicating strong performance expectations for the remainder of the year [1] - The growth rate of the company's profits has outpaced the revenue growth across various profit metrics, highlighting operational efficiency and profitability improvements [1]

Core Insights - WuXi AppTec (603259.SH, 2359.HK) reported its Q3 financial results on October 26, 2025, showcasing strong growth in revenue and profit [1] Financial Performance - The company achieved a cumulative revenue of 32.86 billion yuan for the first three quarters, representing a year-on-year increase of 18.6% [1] - Adjusted Non-IFRS net profit attributable to the parent company reached 10.54 billion yuan, marking a year-on-year growth of 43.4%, which has already matched the total scale of the previous year [1] - The third quarter alone saw record-high revenue and adjusted net profit, indicating the best quarterly performance in the company's history [1]

Core Insights - WuXi AppTec (603259.SH/2359.HK) reported a strong performance in Q3 2025, achieving a record quarterly revenue exceeding 12 billion yuan [1] - The company's revenue for the first three quarters reached 32.86 billion yuan, reflecting a year-on-year growth of 18.6% [1] - Profit growth across three metrics also showed double-digit increases, indicating robust operational efficiency and financial management [1] - Operating cash flow for the first three quarters was 10.87 billion yuan, marking a significant year-on-year increase of 35% [1]

Core Insights - WuXi AppTec (603259.SH) reported a revenue of RMB 32.857 billion for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached RMB 12.076 billion, showing a significant increase of 84.84% year-on-year [1] - The net profit after deducting non-recurring gains and losses was RMB 9.522 billion, up by 42.51% year-on-year [1] Group 1: Chemical Business - The chemical business generated revenue of RMB 25.98 billion, reflecting a year-on-year growth of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds to clients in the past twelve months [1] - In the first three quarters of 2025, the company converted 250 molecules from research to development [1] Group 2: Small Molecule Development and Manufacturing (D&M) - The small molecule D&M business achieved revenue of RMB 14.24 billion, with a year-on-year increase of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 Phase III clinical projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] Group 3: TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching RMB 7.84 billion, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES' order backlog grew by 17.1% year-on-year [3] - The number of clients served in TIDES D&M increased by 12%, and the number of molecules served rose by 34% [3]

Core Insights - WuXi AppTec (603259.SH) reported a revenue of 32.857 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 18.61% [1] - The net profit attributable to shareholders reached 12.076 billion yuan, with a significant year-on-year increase of 84.84% [1] - The net profit excluding non-recurring gains and losses was 9.522 billion yuan, reflecting a year-on-year growth of 42.51% [1] Chemical Business - The chemical business generated revenue of 25.98 billion yuan, marking a year-on-year increase of 29.3% [1] - The small molecule drug discovery ("R") business has successfully synthesized and delivered over 430,000 new compounds for clients in the past twelve months [1] - The company has converted 250 molecules from research to development (R to D) in the first three quarters of 2025 [1] Small Molecule Development and Manufacturing - The small molecule development and manufacturing (D&M) business reported revenue of 14.24 billion yuan, showing a year-on-year growth of 14.1% [2] - A total of 621 new molecules were added to the small molecule D&M pipeline in the first three quarters of 2025, bringing the total to 3,430, which includes 80 commercial projects and 87 clinical phase III projects [2] - The company successfully passed FDA inspections at its Changzhou and Taixing API bases with zero defects in March 2025 [2] TIDES Business - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 7.84 billion yuan, a year-on-year increase of 121.1% [3] - As of September 2025, TIDES orders on hand grew by 17.1% year-on-year, with the number of clients served increasing by 12% and the number of molecules served rising by 34% [3] - The company completed the capacity expansion for peptides in Taixing ahead of schedule, increasing the total volume of solid-phase synthesis reactors to over 100,000 liters [3]